Skip to main content
Clinical Trials/NCT05510817
NCT05510817
Recruiting
N/A

Multiparametric Clinical, Radiological, Neuropsychological, and Neurophysiological Assessment to Investigate Prognostic Factors for Disease Evolution and Treatment Response in MS: a Prospective Study.

University Hospital of Mont-Godinne1 site in 1 country50 target enrollmentJune 6, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Multiple Sclerosis, Relapsing-Remitting
Sponsor
University Hospital of Mont-Godinne
Enrollment
50
Locations
1
Primary Endpoint
evaluation of evolutionary patterns of cognitive status (impaired vs non impaired)/changes from baseline
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This prospective study combining non conventional MRI techniques, neuropsychological screening tools, and a neurophysiological work-up using a sensitive and validated battery, will evaluate the predictive value of these measures and will explore the changes of the cognitive scores from baseline.

Detailed Description

Neurologists are in need for reliable and robust predictive factors enabling to predict disease evolution and treatment response. Moreover, recent studies suggested that the evolution patterns of cognitive status in MS could be mixed, contradicting the concept that cognitive impairment in MS will inevitably increase over time. The main aim of this prospective study is to investigate the predictors of disease evolution, as measured by the EDSS score, using a multiparametric assessment combining neuropsychological tests (BCcogSEP battery), MRI-derived metrics (volumetric brain parameters, tractography, diffusion tensor imaging and fiber tracking), patient-reported outcome measures, and neurophysiological tools (multimodal evoked potentials), and to explore the evolutionary patterns of cognitive status (changes from baseline). The investigators planned to include 50 patients with active RRMS and initiating a new disease-modifying treatment. Yearly assessment starting from study inclusion will be performed.

Registry
clinicaltrials.gov
Start Date
June 6, 2022
End Date
June 6, 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital of Mont-Godinne
Responsible Party
Principal Investigator
Principal Investigator

Frédéric London

Principal Investigator

University Hospital of Mont-Godinne

Eligibility Criteria

Inclusion Criteria

  • active MS, according to the Lublin criteria
  • disease duration \< 10 years before initiating or changing a disease-modifying therapies,
  • relapse- and steroid-free for at least 1 month before MRI acquisition
  • between 18-50 years old
  • having given informed consent
  • with no significant comorbidity other than MS or substance abuse that could interfere with cognitive performances

Exclusion Criteria

  • progressive forms of MS

Outcomes

Primary Outcomes

evaluation of evolutionary patterns of cognitive status (impaired vs non impaired)/changes from baseline

Time Frame: 3 years

changes from baseline in cognitive scores

baseline predictors of future cognitive impairment

Time Frame: 3 years

abnormal cognitive performances based on cognitive scores (using BCcogSEP battery)

Predictors of disease evolution

Time Frame: 3 years

EDSS score worsening from baseline

Secondary Outcomes

  • predictive role of mEPS in predicting future disability(3 years)
  • alteration in strategic white matter tracts at the early stages of RRMS, in patients with and without cognitive impairment(3 years)

Study Sites (1)

Loading locations...

Similar Trials